Clobazam: An effective add‐on therapy in refractory status epilepticus. (12th May 2015)

• Record Type: Journal Article
• Authors: Sivakumar, Sanjeev; Ibrahim, Mohammad; Parker, Dennis; Norris, Gregory; Shah, Aashit; Mohamed, Wazim
• Is Part Of: Epilepsia. Volume 56:issue 6(2015:Jun.)
• Page Start: e83
• Page End: e89
• Publication Date: 2015-05-12
• Subjects: Epilepsy -- Periodicals; 616.853
• DOI: 10.1111/epi.13013
• Languages: English
• ISSNs: 0013-9580

Abstract

<abstract abstract-type="main" id="epi13013-abs-0001"> <title>Summary</title> <p>Refractory status epilepticus (RSE) is a medical emergency, with significant morbidity and mortality. The use and effectiveness of clobazam, a unique 1, 5‐benzodiazepine, in the management of RSE has not been reported before. Over the last 24 months, we identified 17 patients with RSE who were treated with clobazam in our hospital. Eleven of the 17 patients had prior epilepsy. Fifteen patients had focal status epilepticus. Use of clobazam was prompted by a favorable pharmacokinetic profile devoid of drug interactions. Clobazam was introduced after a median duration of 4 days and after a median of three failed antiepileptic drugs. A successful response, defined as termination of RSE within 24 h of administration, without addition or modification of concurrent AED and with successful wean of anesthetic infusions, was seen in 13 patients. Indeterminate response was seen in three patients, whereas clobazam was unsuccessful in one patient. Clobazam averted the need for anesthetic infusions in five patients. Clobazam was well tolerated, and appears to be an effective and promising option as add‐on therapy in RSE. Its efficacy, particularly early in the course of SE, should be further investigated in prospective, randomized trials.</p> </abstract>